Viva Biotech (01873) sold its equity to an investment incubator company.

VIVA Biotech (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer Sobi US Holding Corp. has agreed to acquire Arthrosi Therapeutics through a merger. Following the completion, the company will no longer hold any equity in Arthrosi Therapeutics. The prepayment amount specified in the merger agreement at completion is $950 million (subject to customary adjustments) and a contingent consideration of up to $550 million. Arthrosi Therapeutics is a clinical-stage biotechnology company based in Delaware, focusing on the development of pozdeutinurad, a potential best-in-class, highly efficient, and highly selective next-generation URAT1 inhibitor, aimed at reducing serum uric acid levels in patients with progressive gout, reducing acute attacks, and gout stones. As of the date of this announcement, Viva Biotech holds approximately 3.14% of the equity in Arthrosi Therapeutics (calculated on a fully diluted and converted basis). The Board believes that the merger will allow the group to realize the long-term accumulated investment value in Arthrosi Therapeutics since its initial investment, and presents an opportunity to strengthen the group's financial flexibility. The group intends to use the proceeds from the merger to supplement the group's operating capital and support the growth and development of the group's other investments and incubation business.